8-K: DiaMedica Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

DiaMedica Therapeutics reported its Q1 2025 financial results, highlighting progress in its DM199 clinical trials for preeclampsia and acute ischemic stroke, and anticipates topline preeclampsia data in the near term.

Summary

• DiaMedica Therapeutics announced its financial results for the quarter ended March 31, 2025.
• The company is focused on developing DM199 for acute ischemic stroke and preeclampsia.
• Topline results from the DM199 Preeclampsia Phase 2 Part 1A trial are expected in the near term, with Part 1B initiation anticipated in Q3 2025.
• A KOL event is scheduled for May 28, 2025, to discuss preeclampsia and the DM199 Phase 2 study design.
• Enrollment in the Acute Ischemic Stroke Phase 2/3 program is progressing as planned.
• The company's cash runway extends into Q3 2026.
• Cash, cash equivalents, and short-term investments totaled $37.3 million as of March 31, 2025, compared to $44.1 million as of December 31, 2024.
• Net cash used in operating activities for the quarter was $7.1 million, compared to $6.7 million in the same period of 2024.
• The net loss for the quarter was $7.7 million, or $0.18 loss per share, compared to a net loss of $5.2 million, or $0.14 loss per share, for the quarter ended March 31, 2024.
• R&D expenses were $5.7 million, compared to $3.7 million for the same period in 2024.
• G&A expenses were $2.5 million, compared to $2.1 million for the same period in 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a larger net loss, it is making progress in its clinical trials and has a cash runway into Q3 2026. The potential for DM199 to address unmet medical needs in preeclampsia and acute ischemic stroke is a positive factor.

Positives

• The company has a cash runway into Q3 2026, providing financial stability for ongoing clinical trials.
• Enrollment in the ReMEDy2 trial for acute ischemic stroke is progressing as planned.
• The company anticipates topline data from the Preeclampsia Phase 2 Part 1A trial in the near term.
• DiaMedica is hosting a KOL event to discuss the DM199 Phase 2 preeclampsia study.

Negatives

• The company experienced a net loss of $7.7 million, or $0.18 loss per share, for the quarter ended March 31, 2025, which is higher than the $5.2 million loss in the same period of 2024.
• Cash used in operating activities increased to $7.1 million from $6.7 million in the same period of 2024.
• Cash and cash equivalents decreased from $44.1 million as of December 31, 2024, to $37.3 million as of March 31, 2025.

Risks

• The timing of topline safety and efficacy data from the Preeclampsia Phase 2 Part 1A trial is subject to turnaround time for laboratory test results.
• Clinical trials are subject to risks and uncertainties, including potential adverse events or unfavorable results.
• The company's ability to obtain regulatory approval for DM199 is not guaranteed.
• The company relies on third parties to conduct clinical trials, which introduces potential risks.
• The company's ability to continue to obtain funding for its operations is subject to risks and uncertainties.

Future Outlook

The company anticipates topline data from the Preeclampsia Phase 2 Part 1A trial in the near term and expects to initiate Part 1B in Q3 2025. Enrollment in the ReMEDy2 trial is progressing as planned, with an interim analysis expected in the first half of 2026. The company's cash runway extends into Q3 2026.

Management Comments

• With the upcoming release of preliminary topline safety and efficacy results from Part 1A of the Phase 2 preeclampsia study, DiaMedica is entering what we believe will be an exciting phase in the history of our company, said Rick Pauls, President and CEO of DiaMedica Therapeutics.
• Building on this data, we believe DM199 has an opportunity to become a treatment option for preeclampsia, which is among the most underserved conditions in medicine today with no approved therapeutics.

Industry Context

DiaMedica is focused on developing treatments for acute ischemic stroke and preeclampsia, both areas with significant unmet medical needs. The company's DM199 targets these conditions, potentially offering new therapeutic options where few or no approved treatments currently exist.

Comparison to Industry Standards

• There are no approved pharmacologic treatments for preeclampsia in any marketed territory in the world, making DM199 a potential first-in-class treatment if approved.
• For acute ischemic stroke, DM199 is being developed for patients presenting within 4.5 to 24 hours of stroke onset, a timeframe where no approved pharmacologic agents currently exist.
• Companies like Boehringer Ingelheim (Activase/TNKase) focus on thrombolytic agents for earlier treatment windows in stroke, while DiaMedica is targeting a later window.
• Other companies are exploring neuroprotective agents and devices for stroke, but DM199's approach of enhancing blood flow and neuronal survival offers a unique mechanism of action.

Stakeholder Impact

• Positive impact on patients suffering from preeclampsia and acute ischemic stroke if DM199 proves to be a safe and effective treatment.
• Potential benefits for shareholders if the company successfully develops and commercializes DM199.
• Continued employment for employees involved in the development and clinical trials of DM199.

Next Steps

• The company will release preliminary topline safety and efficacy data from Part 1A of the preeclampsia Phase 2 trial between the second half of June and the first half of July 2025.
• Part 1B of the Preeclampsia Phase 2 trial is expected to initiate in Q3 2025.
• The company will host a virtual key opinion leader (KOL) event on May 28, 2025.
• An interim analysis of the first 200 patients in the ReMEDy2 trial is expected in the first half of 2026.

Key Dates

Keywords

DM199, preeclampsia, acute ischemic stroke, clinical trials, ReMEDy2, DiaMedica Therapeutics, financial results, biopharmaceutical